about
Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findingsRedox balance and carbonylated proteins in limb and heart muscles of cachectic rats.Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures.Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.Vastus lateralis fiber shift is an independent predictor of mortality in chronic obstructive pulmonary disease.[Inflammation and oxidative stress in respiratory and limb muscles of patients with severe sepsis].Diagnosis of Pulmonary Infarction by Thoracic Ultrasonography.Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer.Regional oxygen saturation index (rSO2) in brachioradialis and deltoid muscle. Correlation and prognosis in patients with respiratory sepsis.Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.Bispectral index in hypercapnic encephalopathy associated with COPD exacerbation: a pilot studyEARLY COPD: determinantes de la aparición y progresión de la enfermedad pulmonar obstructiva crónica en adultos jóvenes. Protocolo de un estudio caso-control con seguimiento[Improvement in quality of life and exercise capacity without muscular biology changes after general training in patients with severe chronic obstructive pulmonary disease]The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexiaAdaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patientsDifferences in micro-RNA expression profile between vastus lateralis samples and myotubes in COPD cachexiaStructural differences in the diaphragm of patients following controlled vs assisted and spontaneous mechanical ventilationEGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
P50
Q26775701-27171A2F-3474-4445-BB0B-5D0CAE0682EBQ33500784-C078EE57-F3F7-4140-947D-46617181B463Q33838191-9C5D308A-5665-4D48-B11C-E9EC82348D4CQ37528272-1201BFEE-AE8C-401A-9144-ED0EA25C6460Q42993162-DCA6575A-CE99-4E5B-8F2F-7D259D694620Q43617973-F27235D8-4219-43BD-934F-F6147B99C4F0Q50054440-E2B472C8-A6B2-4AF4-9072-5343759C30A9Q50456022-68BBE312-3ECF-4A7E-BE02-22327870CCE0Q50478765-4D744BA6-0CD4-42E0-8602-9F779CDCFA5CQ51530637-61FC577A-B736-41D4-A158-10F426881243Q57491726-000F9BC0-9AF2-438E-B02F-521B64EEE708Q64135192-BCA315E1-A099-4D9F-B7B9-91B0F2F43259Q83727733-5944C52F-4C51-4571-92C0-DB4821973B3BQ88340125-08DCD274-AA59-46C7-B9C9-8C6CB6F748B7Q90049694-9E407683-F369-4DF1-9E70-0DD611FE7A85Q90448186-A8AB5EC1-8A89-4694-B95D-814018DC0B27Q91795895-79984F18-DEC4-4D37-8801-B0E7576D8EBAQ93182436-8213CD99-A4A9-4CCB-A512-083DBE521083
P50
description
researcher ORCID ID = 0000-0002-6567-0916
@en
name
Sergi Pascual-Guardia
@ast
Sergi Pascual-Guardia
@en
Sergi Pascual-Guardia
@es
Sergi Pascual-Guardia
@nl
type
label
Sergi Pascual-Guardia
@ast
Sergi Pascual-Guardia
@en
Sergi Pascual-Guardia
@es
Sergi Pascual-Guardia
@nl
prefLabel
Sergi Pascual-Guardia
@ast
Sergi Pascual-Guardia
@en
Sergi Pascual-Guardia
@es
Sergi Pascual-Guardia
@nl
P1153
54939778800
P21
P31
P496
0000-0002-6567-0916